促排卵中人绒毛膜促性腺激素扳机时机与药物选择

史潇; 全松

doi:10.7504/fk2014120105

PDF(996 KB)

中国实用妇科与产科杂志 ›› 2015, Vol. 31 ›› Issue (1) : 24-28. DOI: 10.7504/fk2014120105

专题笔谈

促排卵中人绒毛膜促性腺激素扳机时机与药物选择

史潇，全松

作者信息 +

Timing of HCG trigger and choice of triggering-drugs during ovulation induction.

SHI Xiao, QUAN Song.

Author information +

文章历史 +

摘要

人绒毛膜促性腺激素（HCG）扳机目的在于促进卵母细胞最后成熟与排卵，此为促排卵中的关键点之一，并与治疗结局密切相关。促排卵周期中HCG的扳机时机主要依赖于对卵泡径线、血中雌孕激素水平和子宫内膜情况等进行综合分析、判断来确定。HCG扳机的药物有HCG制剂和促性腺激素释放激素激动剂（GnRH-a）两种，针对患者和促排卵方案合理选择不同的药物扳机排卵，其对改善助孕结局和降低促排卵并发症有益。

Abstract

Abstract:HCG trigger is important for inducing oocyte maturation and ovulation induction, which has also been thought one of the key points of ovulation induction and is closely related to the outcomes of ovulation induction.The timing of HCG trigger mainly depends on follicular diameter, serum estrogen and endometrial situation during ovulation induction. HCG and GnRH-a can be used for triggering during ovulation induction. The reasonable choice of triggering-drugs should be made according to different patients and ovulation induction protocols，which will be great helpful to improve the outcomes and decrease the complications.

导出引用

史潇，全松. 促排卵中人绒毛膜促性腺激素扳机时机与药物选择[J]. 中国实用妇科与产科杂志. 2015, 31(1): 24-28 https://doi.org/10.7504/fk2014120105

SHI Xiao, QUAN Song.. Timing of HCG trigger and choice of triggering-drugs during ovulation induction.[J]. Chinese Journal of Practical Gynecology and Obstetrics. 2015, 31(1): 24-28 https://doi.org/10.7504/fk2014120105

中图分类号： R321-33

参考文献

[1］庄广伦. 现代辅助生殖技术［M］.北京：人民卫生出版社，2005：108-110.

[2］ Humaidan P, Alsbjerg B. GnRHa trigger for final oocyte maturation: is HCG trigger history? ［J］.Reprod Biomed Online，2014,29(3):274-280.

[3］ Conti M, Hsieh M, Musa ZA, et al. Novel signaling mechanisms in the ovary during oocyte maturation and ovulation［J］. Mol Cell Endocrinol, 2012 356(1-2):65-73.

[4］朱桂金,徐蓓,聂睿.促性腺激素峰的作用与人绒毛膜促性腺激素诱发排卵［J］.生殖医学杂志,2012,21(6):539-543.

[5］全松, 陈雷宁. 宫腔内人工授精与促排卵［M］.北京：人民卫生出版社，2011：78-89，140-150.

[6］ da Silva AL, Arbo E, Fanchin R.Early versus late HCG administration to trigger ovulation in mild stimulated IUI cycles: a randomized clinical trial［J］. Eur J Obstet Gynecol Reprod Biol, 2012, 164(2):156-160.

[7］ Shalom-Paz E, Marzal A, Wiser A, et al. Does optimal follicular size in IUI cycles vary between clomiphene citrate and gonadotrophins treatments?［J］. Gynecol Endocrinol,2014,30(2):107-110.

[8］ Jayaprakasan K, Hopkisson JF, Campbell BK, et al. Quantification of the effect of pituitary down-regulation on 3D ultrasound predictors of ovarian response ［J］. Hum Reprod, 2009, 23(7):1538-1544.

[9］崔艳国,全松,邢福祺，等.COH周期中卵泡径线大小与体外受精-胚胎移植妊娠率的相关性［J］.广东医学,2007,28(5):753-755.

[10］方媛媛,王秀霞. 人绒毛膜促性腺激素注射日卵泡大小与体外受精-胚胎移植妊娠率的关系［J］. 中国实用妇科与产科杂志,2010, 26(7):543-545.

[11］李艳辉,高颖,耿育红,等. 不同hCG日判定标准对IVF/ICSI-ET治疗结局的影响［J］. 国际生殖健康/计划生育杂志,2014,33(3):232-235.

[12］蔡素芬,张顺吉,龚斐. 控制性超促排卵中人绒毛膜促性腺激素最佳扳机时间的探讨［J］. 生殖与避孕,2012,32(9):607-612.

[13］ Wu Z, Li R, Ma Y, et al. Effect of HCG-day serum progesterone and oestradiol concentrations on pregnancy outcomes in GnRH agonist cycles［J］. Reprod Biomed Online, 2012,24(5):511-520.

[14］ Ta?kin EA, Atabekoälu CS, Musali N, et al. Association of serum estradiol levels on the day of hCG administration with pregnancy rates and embryo scores in fresh ICSI/ET cycles down regulated with either GnRH agonists or GnRH antagonists ［J］. Arch Gynecol Obstet, 2014,289(2):399-405.

[15］丁晨,赵淑芹. HCG日单个卵泡雌激素水平对IVF结局的影响［J］. 中国优生与遗传杂志,2012,20(11):108-110.

[16］ Orvieto R, Zohav E, Scharf S, et al. The influence of estradiol/follicle and estradiol/oocyte ratios on the outcome of controlled ovarian stimulation for in vitro fertilization［J］. Gynecol Endocrinol, 2007, 23(2):72-75.

[17］ Var T, Tonguc E, Dogan M, et al.Relationship between the oestradiol/oocyte ratio and the outcome of assisted reproductive technology cycles with gonadotropin releasing hormone agonist［J］. Gynecol Endocrinol, 2011,27(8):558-561.

[18］倪郝,陈雷宁,全松,等. 长方案垂体降调节行IVF-ET时雌二醇水平变化的意义［J］. 南方医科大学学报,2011,31(2):365-368.

[19］ Zhao J, Zhang Q, Li Y. The effect of endometrial thickness and pattern measured by ultrasonography on pregnancy outcomes during IVF-ET cycles［J］. Reprod Biol Endocrinol, 2012, 100 (1):1-6.

[20］ Zhao J, Zhang Q, Wang Y, et al. Endometrial pattern, thickness and growth in predicting pregnancy outcome following 3319 IVF cycle［J］. Reprod Biomed Online, 2014, 29(3): 291-298.

[21］ Lamanna G, Scioscia M, Lorusso F,et al. Parabolic trend in endometrial thickness at embryo transfer in in vitro fertilization/intracytoplasmic sperm injection cases with clinical pregnancy evidence［J］. Fertil Steril, 2008, 90(4):1272-1274.

[22］ Xu B, Li Z, Zhang H, et al. Serum progesterone level effects on the outcome of in vitro fertilization in patients with differentovarian response: analysis of more than 10,000 cycles［J］. Fertil Steril, 2012,97(6):1321-1327.

[23］ Youssef MA, Al-Inany HG, Aboulghar M, et al. Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles［J］. Cochrane Database Syst Rev, 2011, 13(4):CD003719.

[24］ Madani T, Mohammadi YL, et al. Comparing the efficacy of urinary and recombinant hCG on oocyte/follicle ratio to trigger ovulation in women undergoing intracytoplasmic sperm injection cycles: a randomized controlled trial［J］. J Assist Reprod Genet, 2013, 30(2):239-245.

[25］ Humaidan P, Kol S, Papanikolaou EG, et al. GnRH agonist for triggering of final oocyte maturation: time for a change of practice?［J］. Hum Reprod Update, 2011, 17(4):510-524.

[26］ Castillo JC, Humaidan P, Bernabéu R. Pharmaceutical options for triggering of final oocyte maturation in ART［J］. Biomed Res Int, 2014，2014:580171.

[27］ Lin MH, Wu FS, Lee RK, et al. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles［J］. Fertil Steril, 2013,100(5):1296-1302.

[28］ Griffin D, Benadiva C, Kummer N, et al. Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders［J］. Fertil Steril, 2012, 97(6):1316-1320.